Send us a text

Robert Stone is the CEO of City of Hope ( https://www.cityofhope.org/robert-stone ), a premier cancer research and treatment center dedicated to innovation in biomedical science and the delivery of compassionate, world-class patient care. A seasoned health care executive, he has served in a number of strategic decision-making roles since he joined City of Hope in 1996, culminating with his appointment as president in 2012, CEO in 2014, and as the Helen and Morgan Chu Chief Executive Officer Distinguished Chair in 2021.

Mr. Stone has J.D., University of Chicago Law School, Chicago, IL.

Mr. Stone’s strategic acumen, empathy and visionary leadership have driven City of Hope’s rapid evolution.

As an independent institution dedicated to advancing the fight against cancer and diabetes, City of Hope is accelerating opportunities for high-impact discovery and ensuring that patients around the world have access to the most advanced therapies. Recent examples include a groundbreaking alliance in precision medicine with the Translational Genomics Research Institute (TGen), a leader in genomic analysis and bioinformatics; leadership in CAR T cell therapy research and therapy; and an innovative program to offer cancer support services to the employees of some of American’s largest employers, regardless of geography.


Dr. Marcel van den Brink, M.D., Ph.D.( https://www.cityofhope.org/marcel-van-den-brink ), is President of City of Hope Cancer Center, main campus in Los Angeles, and National Medical Center, chief physician executive and the Deana and Steve Campbell Chief Physician Executive Distinguished Chair, and is a globally recognized leader in the basic and translational science of bone marrow transplantation (BMT), the microbiome and cancer immunotherapy. His specialties include immune reconstitution and graft-versus-host disease — side effects many BMT patients experience — as well as the impact of the microbiome on immunotherapy for cancer.

A researcher who has opened new fields of investigation and improved patient outcomes, Dr. Van den Brink has pursued innovative ways to improve and optimize BMT, developing strategies to make the process less toxic and lower the rate of recurrence. Throughout his career, he has maintained an intense focus on converting scientific discoveries in his laboratory into better therapies for patients around the world.

Dr. Van den Brink joined City of Hope in part because of their shared commitment to advancing the frontiers of cancer care and research. He is known for his inclusive approach to leadership and his devotion to providing junior faculty colleagues with mentorship and career development opportunities.

A recipient of numerous national and international awards, Dr. Van den Brink is a member of the Royal Netherlands Academy of Arts and Sciences. Among many leadership roles, he serves as vice chair of the board for Deutsche Knochenmark Stiftung, a global donor registration that facilitates 40% of all unrelated allogenic blood stem cell donations worldwide.


Dr. Van den Brink has a Ph.D., Medicine (Immunology), and M.D., Cum Laude, University of Leiden, The Netherlands, completed a postdoctoral fellowship at the Pittsburgh Cancer Institute in Pittsburgh, PA and residency at Duke University Medical Center in Durham, NC.


#Cancer #Oncology #CityOfHope #RobertStone #MarcelVanDenBrink #Microbiome #Immunotherapy #CarT #Thymus #ThymicInvolution #Regeneration #BoneMarrowTransplantation #TranslationalGenomicsResearchInstitute #PrecisionMedicine #GraftVersusHostDisease #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show